European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group

• Published in: Clinical infectious diseases 2024-10, Vol.79 (4), p.936-943
• Main Authors: Serris, Alexandra, Rautemaa-Richardson, Riina, Laranjinha, Joana D, Candoni, Anna, Garcia-Vidal, Carolina, Alastruey-Izquierdo, Ana, Hammarström, Helena, Seidel, Danila, Styczynski, Jan, Sabino, Raquel, Lamoth, Frederic, Prattes, Juergen, Warris, Adilia, Porcher, Raphaël, Lanternier, Fanny
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antifungal Agents - adverse effects; Antifungal Agents - therapeutic use; brain infection; central nervous system aspergillosis; cerebral aspergillosis; Clinical Medicine; Europe; Female; Humans; invasive aspergillosis; isavuconazole; Klinisk medicin; Male; Middle Aged; Neuroaspergillosis - drug therapy; Nitriles - adverse effects; Nitriles - therapeutic use; Pyridines - adverse effects; Pyridines - therapeutic use; Retrospective Studies; Treatment Outcome; Triazoles - adverse effects; Triazoles - therapeutic use; Voriconazole - therapeutic use; Young Adult
• ISSN: 1058-4838; 1537-6591; 1537-6591
• DOI: 10.1093/cid/ciae371

Cerebral aspergillosis (CA) is associated with high mortality. According to the European Conference on Infections in Leukemia and the European Society of Clinical Microbiology and Infectious Diseases guidelines, the recommended first-line treatment for all forms of aspergillosis is voriconazole or isavuconazole. However, little is known about the efficacy and safety of isavuconazole in CA. We conducted a European multicenter retrospective study of patients treated with isavuconazole for proven or probable CA between 2014 and 2022 and compared the outcomes with those of weighted control groups from the previously published French national cohort of CA, the Cerebral Aspergillosis Lesional Study (CEREALS). Forty patients from 10 countries were included. The main underlying conditions were hematological malignancies (53%) and solid-organ transplantation (20%). Isavuconazole was administered as a first-line treatment to 10 patients, primarily in combination therapy, resulting in control of CA in 70% of these cases. Thirty patients received isavuconazole after a median of 65 days on another therapy, mostly because of side effects (50%) or therapeutic failure (23%) of the previous treatment. Predominantly given as monotherapy, it achieved control of CA in 73% of the patients. Seventeen patients (43%) underwent neurosurgery. When measured, isavuconazole levels were low in cerebrospinal fluid but adequate in serum and brain tissue. Isavuconazole toxicity led to treatment interruption in 7.5% of the patients. Twelve-week mortality was 18%. Comparison with the CEREALS cohort showed comparable survival in patients receiving isavuconazole or voriconazole as a first-line treatment. Isavuconazole appears to be a well-tolerated treatment. Mortality of CA treated with isavuconazole is similar to that reported with voriconazole.